ClinicalTrials.gg
RecruitingNCT07444385Updated Mar 3, 2026

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 in Healthy Adult Male Subjects

A Phase 1 interventional study of AD-116, AD-1161 in Benign Prostatic Hyperplasia, sponsored by Addpharma Inc.. Recruiting at 1 site in South Korea. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-03.

Sponsored by Addpharma Inc. (part of Yuhan Corporation) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of — 6 open to participants now, 6 under way, none of them phase 3. Prostatic Hyperplasia · Korea, Republic of.

Planned enrollment
36th of 57
44 · median 83
Started
2026
with 6 others
Phase 1
20 of 72
4 open now
Registered
68th of 72
by date
Lead sponsor
4 of 72
Addpharma Inc.

Among the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, this one is the 36th largest by planned enrollment of the 57 interventional ones that give a count, is one of 7 that started in 2026, is one of 20 in phase 1, and was the 68th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 181 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

6 of the 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 19 Years and older · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 72 studies in Prostatic Hyperplasia with a site in Korea, Republic of, or all of them as a file.
02

Study summary

A Study to Evaluate the Safety and Pharmacokinetics of AD-116 and AD-1161 Under Fed Conditions in Healthy Adult Male Subjects

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight equal to or greater than 50kg and (BMI) between 18.0 kg/m2 and 30.0 kg/m2 at the time of screening visit
  • The Age equal to or greater than 19 in healthy adult male volunteers at the time of screening visit

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an drug within the 6 months from scheduled first administration
  • Other exclusions applied
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Sequence A

    Period 1 : Reference Drug(Duodart capsule), Period 2 : Test Drug(dutasteride 0.5 mg / tamsulosin 0.4 mg) Single-dose oral administration of AD-1161 (dutasteride 0.5 mg / tamsulosin 0.4 mg) in Period 1, followed by single-dose oral administration of AD-116 (Duodart capsule) in Period 2.

    Drug: AD-116, AD-1161

  • Experimental
    Sequence B

    Period 1 : Test Drug(dutasteride 0.5 mg / tamsulosin 0.4 mg), Period 2 : Reference Drug(Duodart capsule) ) Single-dose oral administration of AD-116 (Duodart capsule) in Period 1, followed by single-dose oral administration of AD-1161 (dutasteride 0.5 mg / tamsulosin 0.4 mg) in Period 2.

    Drug: AD-116, AD-1161

Interventions

  • DrugAD-116, AD-1161

    Single-dose oral administration of AD-116 or AD-1161, according to randomized sequence.

06

What researchers measure

Primary outcomes

  1. Area under the plasma concentration-time curve during dosing interval (AUCt)

    AUCt of AD-116

    Time frame: pre-dose (0hour) to 72hours

  2. Maximum concentration of drug in plasma (Cmax)

    Cmax of AD-116

    Time frame: pre-dose (0hour) to 72hours

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Apr 2026, 1 month after the start.

Of 26 industry-sponsored phase 1 interventional studies under Prostatic Hyperplasia, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 4. This study's planned 1 month is below that.

Counting every sponsor, half of 34 studies reached it within 3 months; a quarter within 1 and three quarters within 6.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2026
First posted
Mar 2, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Apr 22, 2026
CompletionEst.
May 8, 2026
Last update
Mar 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444385
Lead sponsor
Addpharma Inc.
Responsible party
Sponsor
First posted
Mar 2, 2026
Start date
Feb 26, 2026
Primary completion
Apr 22, 2026 (estimated)
Completion
May 8, 2026 (estimated)
Last update
Mar 3, 2026

Study contacts

JaeHun Jung
Contact
jhjung@addpharma.co.kr
+82-31-891-5683

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion